Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.
GI Cancer ASCO 2024 Highlights
Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.
Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.
The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.
Mark A. Lewis, MD, discusses recent data from the COMMIT trial investigating first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
3
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
4
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
5